Skip to content

A prospective study of endoscopic nipple-sparing mastectomy combined with immediate autologous fat grafting reconstruction or prosthesis reconstruction for breast cancer patients

A prospective study of endoscopic nipple-sparing mastectomy combined with immediate autologous fat grafting reconstruction or prosthesis reconstruction for breast cancer patients

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400086115
Enrollment
Unknown
Registered
2024-06-25
Start date
2024-06-30
Completion date
Unknown
Last updated
2024-07-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Interventions

A:Endoscopic nipple-sparing mastectomy (NSM) combined with immediate autologous fat grafting reconstruction
B:Endoscopic nipple-sparing mastectomy (NSM) combined with immediate prosthesis reconstruction

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: ? Female, aged 18-70 years old; ? BMI = 18; ? cT1-2N0M0, pathological examination confirms breast cancer (including carcinoma in situ); ? Endoscopic nipple-sparing mastectomy (NSM) was performed for breast cancer, and the estimated breast volume was = 200ml; ? Postoperatively receiving standard adjuvant therapy; ? Voluntarily participate in this study, sign informed consent, have good compliance, and are willing to cooperate with follow-up.

Exclusion criteria

Exclusion criteria: ? Pregnant and lactating women; ? Patients with breast cancer above T3 or N1 at the time of diagnosis; ? Accept preoperative neoadjuvant therapy; ? Bilateral breast cancer; ? Individuals who cannot tolerate surgery or voluntarily give up surgical treatment due to dysfunction of important organs such as the heart, brain, and lungs; ? The researchers believe that the patient is not suitable to participate in any other circumstances of this study.

Design outcomes

Primary

MeasureTime frame
Aesthetic outcome;Safety;

Secondary

MeasureTime frame
Adverse events;Ipsilateral breast cancer local recurrence rate;;

Countries

China

Contacts

Public ContactRui Xu

Guangdong Provincial Hospital of Chinese Medicine

catdoctor007@163.com+86 189 0306 8226

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026